FDA gives Sanofi TB drug another approval; Italian court upholds antitrust fines against Roche, Novartis;

@FiercePharma: ICYMI yesterday: Reuters: In Fresenius, Danone could lose second suitor for nutrition unit. Item | Follow @FiercePharma

@CarlyHFierce: Reuters: In Fresenius, Danone could lose second suitor for nutrition unit. More | Follow @CarlyHFierce

> The FDA has approved Sanofi's ($SNY) Priftin in combination with isoniazid for a new indication, in the treatment of latent tuberculosis infection. Story

> Italy's Lazio regional administrative court on has upheld an antitrust fine of €180 million against Novartis ($NVS) and Roche ($RHHBY), accused of forming a cartel to promote the more expensive eye drug Lucentis over Roche's Avastin. Report

> The European Medicines Agency will look for a new executive director after Guido Rasi stepped aside following a EU commission decision that his selection was flawed. Story

> Ranbaxy Laboratories is reportedly in talks with the Competition Commission of India about what products it might sell there to gain approval of its merger with Sun Pharmaceutical. Story

> GW Pharmaceuticals blamed higher R&D costs for steeper full-year losses.

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic gets EU regulatory green light for $43 billion merger with Covidien. Article | Follow @FierceMedDev

@EmilyWFierce: Roche acquires prenatal diagnostics outfit Ariosa. Press release | Follow @EmilyWFierce

> Medtronic sells $17B in bonds to fund Covidien buy. Story

> Masimo wireless, wearable patient monitor cleared by FDA. More

> Edison Nation and Mount Sinai team up for device innovation. Article

> FDA approves Animas insulin pump, continuous glucose monitor combo device. Report

Biotech News

@FierceBiotech: From FierceBiotechIT: Texas' $3B cancer agency makes computational biology a priority. Article | Follow @FierceBiotech

@JohnCFierce: I wonder if someone would pay me $3.5B for Uncle John's Quiet Time Elixir. (Nyquil and bourbon). $AVNR. | Follow @JohnCFierce

@DamianFierce: Tim Duncan donated $247K to help sequence the genomes of 1,000 cancer patients and publicize the results. Article | Follow @DamianFierce

> J&J scuttles a $945M arthritis deal with Astellas on the eve of Phase III. News

> GeNeuro snags a $455M deal, inks MS drug pact with Servier. More

> Otsuka buys Avanir and its portfolio of repurposed generics for $3.5B. Story

> Ascendis banks $60M to get its orphan drug into Phase III. Article

Biotech Research News

> New structural biology software tackles viruses and bacteria. Story

> 8-year study highlights role of a key protein in cardiomyopathy. More

> Binge drinking 'cure' in rats sparks a debate over animal study. Story

> Cell research at Brigham & Women's points to a new drug target for fibrosis. Report

> Harvard, MIT teams identify a 'pre-malignant' phase for blood cancers. Article

Pharma Manufacturing News

> Lyophilization market forecast to double in size by 2020. Article

> FDA slaps Dr. Reddy's with a Form 483. Report

> Eisai opens new plants targeting Asia and Europe. More

> Italy clears Novartis vaccine manufacturing in deaths following vaccinations. Story

> Recipharm expands footprint, buys Flamel facility in France for $13.2M. Article

And Finally... People diagnosed with diabetes in their 50's are significantly more likely than others to suffer mental decline by their 70's, researchers have found. More

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.